Year: 2007
Type: article
Abstract: BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (ClinicalTrials.gov number, NCT00379041 [ClinicalTrials.gov].).
Source: New England Journal of Medicine
DOI: 10.1056/nejmoa064601
Authors: Christophe Fermé, Houchingue Eghbali, Jacobus H. Meerwaldt, Chantal Rieux, Jacques Bosq, Françoise Berger, Théodore Girinsky, Pauline Brice, Mars B. van't Veer, Jan A. Walewski, Pierre Lederlin, Umberto Tirelli, Patrice Carde, Eric Van Den Neste, Emmanuel Gyan, Mathieu Monconduit, Marine Diviné, John M.M. Raemaekers, Gilles Salles, Evert M. Noordijk, Geert-Jan Creemers, Jean Gabarre, Anton Hagenbeek, Oumédaly Reman, Michel Blanc, José Thomas, Brigitte Vié, Johanna C. Kluin-Nelemans, Fernando Viseu, Joke W. Baars, Philip Poortmans, Pieternella J. Lugtenburg, Christian Carrie, Jérôme Jaubert, Michel Henry-Amar
Institutions: Institut Gustave Roussy, Institut Bergonié, Medisch Spectrum Twente, Centre François Baclesse, Lyon 1 Université, Hospices Civils de Lyon, Hôpital Saint-Louis, Daniel den Hoed Kliniek, The Maria Sklodowska-Curie National Research Institute of Oncology, Centre Hospitalier Régional et Universitaire de Nancy, Centro di Riferimento Oncologico, Cliniques Universitaires Saint-Luc, Centre Henri Becquerel, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Radboud University Medical Center, Leiden University Medical Center, Catharina Ziekenhuis, Pitié-Salpêtrière Hospital, University Medical Center Utrecht, Centre Hospitalier Universitaire de Caen Normandie, Universitair Ziekenhuis Leuven, IPO Porto, The Netherlands Cancer Institute, Ignatius Hospital, Erasmus MC, Centre Léon Bérard, Centre Hospitalier Universitaire de Saint-Étienne
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2125790189
